Page 1504 - Williams Hematology ( PDFDrive )

1478 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1479

diagnosis and for follow-up in chronic myeloid leukemia: A study of 350 cases. Leuke- 381. Michiels JJ, Prins ME, Hagermeijer A, et al: Philadelphia chromosome-positive
mia 16:53, 2002. thrombocythemia and megakaryoblast leukemia. Am J Clin Pathol 88:645, 1987.
350. Yanagi M, Shinjo K, Takeshita A, et al: Simple and reliably sensitive diagnosis and 382. Sanadi I, Yamamoto S, Ogata M, et al: Detection of the Philadelphia chromosome in
monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia chronic neutrophilic leukemia. Jpn J Clin Oncol 15:553, 1985.
by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia 383. Christopoulos C, Kottoris K, Mikraki V, Anevlavis E: Presence of bcr/abl rear-
13:542, 1999. rangement in a patient with chronic neutrophilic leukaemia. J Clin Pathol 49:1013,
351. Werner M, Ewig M, Nasarek A, et al: Value of fluorescence in situ hybridization for 1996.
detecting the bcr/abl gene fusion in interphase cells of routine bone marrow speci- 384. Pane F, Frigeri F, Sindina M, et al: Neutrophilic-chronic myeloid leukemia: A distinct
mens. Diagn Mol Pathol 6:282, 1997. disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood
352. Chase A, Grand F, Zhang JG, et al: Factors influencing the false positive and nega- 88:2410, 1996.
tive rates of BCR-ABL fluorescence in situ hybridization. Genes Chromosomes Cancer 385. Verstovsek S, Lin H, Kantarjian H, et al: Neutrophilic-chronic myeloid leukemia: Low
18:246, 1997. levels of p 230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an
353. Pelz AF, Kroning H, Franke A, Wieacker P: High reliability and sensitivity of the indolent course. Cancer 94:2416, 2002.
BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements. Ann Hematol 386. Ohsaka A, Shiina S, Kobayashi M, et al: Philadelphia chromosome-positive chronic
81:147, 2002. myeloid leukemia expressing p190(BCR-ABL). Intern Med 41:1183, 2002.
354. Hochhaus A, Reiter A, Skladny H, et al: Molecular monitoring of residual disease 387. Barnes DJ, Melo JV: Cytogenetic and molecular genetic aspects of chronic myeloid
in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res leukaemia. Acta Haematol 108:180, 2002.
144:36, 1998. 388. Whang-Peng J, Gralnick HR, Johnson RE, et al: Chronic granulocytic leukemia (CGL)
355. Wells SJ, Phillips CN, Winton EF, Farhi DC: Reverse transcriptase polymerase chain during the course of chronic lymphocytic leukemia (CLL): Correlation of blood, mar-
reaction for bcr-abl fusion in chronic myelogenous leukemia. Am J Clin Pathol row, and spleen morphology and cytogenetics. Blood 43:333, 1974.
105:756, 1996. 389. Schrieber ZA, Axelrod MR, Abebe LS: Coexistence of chronic myelogenous leukemia
356. Cox MC, Maffei L, Buffolino S, et al: A comparative analysis of FISH, RT-PCR, and and chronic lymphocytic leukemia. Cancer 54:697, 1984.
cytogenetics for the diagnosis of bcr-abl-positive leukemias. Am J Clin Pathol 109:24, 390. Specchia G, Buquicchio C, Albano F, et al: Non-treatment-related chronic myeloid
1998. leukemia as a second malignancy. Leuk Res 28:115, 2004.
357. Krackoff IH: Studies of uric acid biosynthesis in the chronic leukemias. Arthritis 391. Esteve J, Cervantes F, Rives S, et al: Simultaneous occurrence of B-cell chronic lym-
Rheum 8:772, 1965. phocytic leukemia and chronic myeloid leukemia with further evolution to lymphoid
358. Vogler WR, Bain JA, Huguley CM Jr, et al: Metabolic and therapeutic effects of allopu- blast status. Haematologica 82:596, 1997.
rinol in patients with leukemia and gout. Am J Med 40:548, 1966. 392. Leoni F, Ferrini PR, Castoldi GL, et al: Simultaneous occurrence of chronic granulo-
359. Zittoun J, Marquet J, Zittoun R: The intracellular content of the three cobalamins at cytic leukemia and chronic lymphoid leukemia. Haematologica 72:253, 1987.
various stages of normal and leukaemic myeloid cell development. Br J Haematol 393. Crescenzi B, Sacchi S, Marasca R, et al: Distinct genomic events in the myeloid and
31:299, 1975. lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and
360. Zittoun J, Zittoun R, Marquet J, Sultan C: The three transcobalamins in myeloprolifer- B-chronic lymphocytic leukemia. Leukemia 16:955, 2002.
ative disorders and acute leukemia. Br J Haematol 31:287, 1975. 394. Mansat-De Mas V, Rigal-Huguet F, Cassar G, et al: Chronic myeloid leukemia asso-
361. Rosner F, Schreiber ZA: Serum vitamin B12 and vitamin B12 binding capacity in ciated with B-cell chronic lymphocytic leukemia: Evidence of two separate clones as
chronic myelogenous leukemia and other disorders. Am J Med Sci 263:473, 1972. shown by combined cell-sorting and fluorescence in situ hybridization. Leuk Lym-
362. Sternman U-H: Intrinsic factor and the B12 binding proteins. Clin Haematol 5:473, phoma 44:867, 2003.
1976. 395. Faguet GB, Little T, Agee JF, Garver FA: Chronic lymphatic leukemia evolving into
363. Corcino JJ, Zalusky R, Greenberg M, Herbert V: Coexistence of pernicious anaemia chronic myelocytic leukemia. Cancer 52:1647, 1983.
and chronic myeloid leukaemia: An experiment of nature involving vitamin B12 396. Jantunen E, Nousiainen T: Ph-positive chronic myelogenous leukemia evolving after
metabolism. Br J Haematol 20:511, 1971. polycythemia vera. Am J Hematol 37:212, 1991.
364. Agis H, Sperr WR, Herndlhofer S, et al: Clinical and prognostic significance of hista- 397. Hoppen EC, Lewis JP: Polycythemia rubra vera progressing to Ph-positive chronic
mine monitoring in patients with CML during treatment with imatinib (STI571). Ann myelogenous leukemia. Ann Intern Med 83:820, 1975.
Oncol 18:1834, 2007. 398. Haq AU: Transformation of polycythemia vera to Ph-positive chronic myelogenous
365. Youman JD, Taddeini L, Cooper T: Histamine excess symptoms in basophilic chronic leukemia. Am J Hematol 356:110, 1990.
granulocytic leukemia. Arch Intern Med 131:560, 1973. 399. Roth AD, Oral A, Przepiorka D, et al: Chronic myelogenous leukemia and acute
366. Rosenthal S, Schwartz JH, Canellos GP: Basophilic chronic granulocytic leukemia lymphoblastic leukemia occurring in the course of polycythemia vera. Am J Hematol
with hyperhistaminemia. Br J Haematol 36:367, 1977. 43:123, 1993.
367. Gomez GA, Sokal JE, Walsh D: Prognostic features at diagnosis of chronic myelocytic 400. Foviester RH, Louro JM: Philadelphia chromosome abnormality in angiogenic mye-
leukemia. Cancer 47:2470, 1981. loid metaplasia. Ann Intern Med 64:622, 1966.
368. Bellevue R, Dosik H, Spergel G, Gussoff BD: Pseudohyperkalemia and extreme leuko- 401. Nowell PC, Kant JA, Finan JB, et al: Marrow fibrosis associated with a Philadelphia
cytosis. J Lab Clin Med 85:660, 1975. chromosome. Cancer Genet Cytogenet 59:89, 1992.
369. Ballard HS, Marcus AJ: Hypercalcemia in chronic myelogenous leukemia. N Engl J 402. Roth DG, Richman CM, Rowley JD: Chronic myelodysplastic syndrome (preleukemia)
Med 282:663, 1970. with the Philadelphia chromosome. Blood 56:262, 1980.
370. Evans JJ, Bozdech MJ: Hypokalemia in nonblastic chronic myelogenous leukemia. 403. Berrebi A, Bruck R, Shtalrid M, Chemke J: Philadelphia chromosome in idiopathic
Arch Intern Med 141:786, 1981. acquired sideroblastic anemia. Acta Haematol 72:343, 1984.
371. Perillie PE, Finch SC: Muramidase studies in Philadelphia-chromosome-positive and 404. Suzan F, Terré C, Garcia I, et al: Three cases of typical aplastic anaemia associated with
chromosome-negative chronic granulocytic leukemia. N Engl J Med 283:456, 1970. a Philadelphia chromosome. Br J Haematol 112:385, 2001.
372. Gilbert HS, Ginsberg H: Hypocholesterolemia as a manifestation of disease activity in 405. Sica S, Chiusolo P, Zollino M, et al: The association of severe aplastic anaemia with
chronic myeloid leukemia. Cancer 51:1428, 1983. the Philadelphia chromosome and the bcr/abl transcript. Br J Haematol 114:961,
373. Muller CP, Wagner AN, Maucher C, Steinke B: Hypocholesterolemia, an unfavorable 2001.
feature of prognostic value in chronic myeloid leukemia. Eur J Haematol 43:235, 1989. 406. Hande K: Hyperuricemia, uric acid nephropathy and the tumor lysis syndrome, in
374. Musolino C, Alonci A, Bellomo G, et al: Levels of soluble angiogenin in chronic mye- Renal Complications of Neoplasia, edited by McKinney TD, p 134. Praeger, New York,
loid malignancies. Eur J Haematol 72:416, 2004. 1986.
375. Calabro L, Fonsatti E, Bellomo G, et al: Differential levels of soluble endoglin (CD105) 407. Navolanic PM, Pui CH, Larson RA, et al: Elitek-rasburicase: An effective means to
in myeloid malignancies. J Cell Physiol 194:171, 2003. prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting
376. Sessarego M, Defferrari R, Dejana AM, et al: Cytogenetic analysis in essential throm- Report, Dallas, TX, January, 2002. Leukemia 17:499, 2003.
bocythemia at diagnosis and at transformation. Cancer Genet Cytogenet 43:57, 1989. 408. Jeha S, Pui CH: Recombinant urate oxidase (rasburicase) in the prophylaxis and treat-
377. Pajor L, Kereskai L, Zsdral K, et al: Philadelphia chromosome and/or bcr-abl ment of tumor lysis syndrome. Contrib Nephrol 147:69, 2005.
mRNA-positive primary thrombocytosis: Morphometric evidence for the transition 409. Liu CY, Sims-McCallum RP, Schiffer CA: A single dose of rasburicase is sufficient for
from essential thrombocythemia to chronic myeloid leukaemia type myeloprolifera- the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 29:463,
tion. Histopathology 42:53, 2003. 2005.
378. Blickstein D, Aviram A, Luboshitz J, et al: BCR-ABL transcripts in bone marrow aspi- 410. Arnold TM, Reuter JP, Delman BS, Shanholtz CB: Use of single-dose rasburicase in an
rates of Philadelphia-negative essential thrombocythemia patients: Clinical presenta- obese female. Ann Pharmacother 38:1428, 2004.
tion. Blood 90:2768, 1997. 411. Bazarbashi MS, Smith MR, Karanes C, et al: Successful management of Ph chromo-
379. Cervantes F, Colomer D, Vives-Corrons JL, et al: Chronic myeloid leukemia of throm- some chronic myelogenous leukemia with leukapheresis during pregnancy. Am J
bocythemic onset: A CML subtype with distinct hematological and molecular fea- Hematol 38:235, 1991.
tures. Leukemia 10:1241, 1996. 412. Strobl FJ, Voelkerding KY, Smith EP: Management of chronic myeloid leukemia dur-
380. Paietta E, Rosen N, Roberts M, et al: Philadelphia chromosome positive essential ing pregnancy with leukapheresis. J Clin Apher 14:42, 1999.
thrombocythemia evolving into lymphoid blast crisis. Cancer Genet Cytogenet 25:227, 413. Kennedy BJ: The evolution of hydroxyurea therapy in chronic myelogenous leukemia.
1987. Semin Oncol 19(Suppl 9):21, 1992.

Kaushansky_chapter 89_p1437-1490.indd 1479 9/18/15 3:42 PM